HAYA Therapeutics Secures $65 Million for RNA-Guided Medicines
Deal News | May 08, 2025 | Broadview Ventures
HAYA Therapeutics has successfully raised $65 million in Series A funding, with significant investment from Broadview Ventures. The funds are earmarked for advancing the company's precision RNA-guided medicines aimed at treating chronic and age-related diseases, a rapidly expanding niche in modern medicine. The considerable investment indicates strong confidence from the investors in HAYA's innovative approach and potential impact on the healthcare industry.
Sectors
- Biotechnology
- Healthcare
- Private Equity and Venture Capital
Geography
- United States – The article involves Broadview Ventures, a U.S.-based PE firm, indicating an American geographical focus.
Industry
- Biotechnology – The article discusses HAYA Therapeutics, which specializes in RNA-guided medicines for chronic and age-related diseases, placing it firmly in the biotech industry.
- Healthcare – HAYA Therapeutics' focus on developing treatments for chronic and age-related diseases classifies it within the healthcare sector.
- Private Equity and Venture Capital – Broadview Ventures' involvement in HAYA Therapeutics' Series A funding represents a venture capital interest in the biotech and healthcare sector.
Financials
- $65 million – This is the amount raised by HAYA Therapeutics in its Series A funding round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| HAYA Therapeutics | Target | Company | HAYA Therapeutics is a company developing precision RNA-guided medicines for chronic and age-related diseases. |
| Broadview Ventures | Investor | Company | Broadview Ventures is a private equity firm involved in venture capital funding, supporting healthcare and biotech innovations. |